‘Blended learning’ is the longer term in a post-Covid world: Experts
According to specialists, colleges and faculties should adapt to the newest studying reforms carried out within the wake of the Covid-19 pandemic and observe a blended method, and lecturers is not going to be the one supply of data sooner or later, a report in ThePrint stated.
Human lecturers and social robots will create a co-bot sort of scenario collectively, and co-learning will happen. Virtual assistants similar to Siri, Alexa and chatbots exist already, making synthetic intelligence part of our lives. The stuff individuals used to consider as science fiction will develop into our new regular within the near-term, stated Bhushan Patwardhan, Vice Chairman, University Grants Commission, at an occasion organised by ThePrint. Education around the globe was disrupted by the Covid outbreak. In India, most academic establishments had been compelled to shut down and, since March 2020, lessons have moved on-line. With almost a yr of digital studying, specialists recommend the one method ahead is to adapt to digital or on-line training. Read more here
Countries which might be signing up for India’s vaccines
As the world seems to be to India to provide vaccines, a report within the BBC offers a glance into the international locations which might be signing up for made-in-India vaccines.
Bhutan, the Maldives, Bangladesh, Nepal, Myanmar and Seychelles have already acquired a number of the first doses. So far, solely Serum Institute of India’s (SII) Covishield has been exported – some within the type of “gifts” and the remaining according to business contracts signed between the vaccine maker and these international locations. AstraZeneca signed a licencing settlement with SII in June final yr to provide one billion doses to low-and middle-income international locations, promising to ship 400 million doses by the tip of 2020. India can also be getting ready to ship doses to Sri Lanka, Afghanistan and Mauritius after regulatory approvals from these international locations. Commercial exports of Covishield vaccine to Brazil have additionally been authorised. Read more here
‘No cardiac involvement’ post-Covid: Study finds
While there are considerations of Covid-19 sufferers creating coronary heart issues, a examine of 280 recovered healthcare staff confirmed no cardiac drawback, a report in The Hindu stated.
Two hundred and eighty well being staff had been evaluated by means of ECG, Echo, X-Ray Chest and Cardiac MRI at Bengaluru’s state-run Sri Jayadeva Institute of Cardiovascular Sciences and Research. The outcomes confirmed “no cardiac involvement”. The ages of the employees diverse from 23 years to 60 years. 15% of them had hypertension and diabetes. None had pre-existing cardiac points. Read more here
13 Co-Win glitches had been recognized throughout dry-runs, 12 ‘resolved’
India’s flagship digital platform to handle the vaccination rollout, Co-Win, had at the least 13 sorts of glitches that had been recognized through the dry-runs, in response to a report in The Hindu.
These glitches embrace the shortage of a system for recording causes if the affected person was not vaccinated, delays within the distribution of the SMS to recipients, the weblink that allowed hostile results to be recorded not working and the software program module not with the ability to account for the vials returned after the completion of the session. Of the 13 snags recognized, 12 have been ‘resolved’, the report stated citing a authorities official. Read more here
Covid vaccine hesitancy in India down by 7% since December
A survey of 17,000 individuals confirmed that Covid-related vaccine hesitancy in India has diminished from 69 per cent in December to 62 per cent in January, in response to a report ThePrint.
LocalCircles, a group social media platform, performed the survey from 16 to 18 January in 230 districts throughout India. Earlier surveys by the platform confirmed vaccine hesitancy had dropped to 59 per cent in November final yr after efficacy outcomes of Pfizer and Moderna vaccines had been introduced—each vaccines are but to come back to India. Vaccine hesitancy, nevertheless, rose to 69 per cent in December after an hostile response was reported for Covishield and trial process-related considerations with one of many Bharat Biotech companions. Read more here